KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Treasury Shares (2018 - 2025)

Amneal Pharmaceuticals has reported Treasury Shares over the past 7 years, most recently at $15.9 million for Q4 2025.

  • Quarterly results put Treasury Shares at $15.9 million for Q4 2025, down 9.74% from a year ago — trailing twelve months through Dec 2025 was $15.9 million (down 9.74% YoY), and the annual figure for FY2025 was $15.9 million, down 9.74%.
  • Treasury Shares for Q4 2025 was $15.9 million at Amneal Pharmaceuticals, down from $17.6 million in the prior quarter.
  • Over the last five years, Treasury Shares for AMRX hit a ceiling of $17.9 million in Q4 2022 and a floor of $15.9 million in Q4 2025.
  • Median Treasury Shares over the past 4 years was $17.5 million (2023), compared with a mean of $17.2 million.
  • Biggest five-year swings in Treasury Shares: rose 0.7% in 2024 and later decreased 9.74% in 2025.
  • Amneal Pharmaceuticals' Treasury Shares stood at $17.9 million in 2022, then decreased by 2.64% to $17.5 million in 2023, then rose by 0.7% to $17.6 million in 2024, then fell by 9.74% to $15.9 million in 2025.
  • The last three reported values for Treasury Shares were $15.9 million (Q4 2025), $17.6 million (Q4 2024), and $17.5 million (Q4 2023) per Business Quant data.